Graft-Versus-Host Disease (GVHD) is a condition that might occur after an allogenic transplant. In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign, and the donated cells/bone marrow attack the body. Some people have a very mild form which doesn’t last long. For others, GvHD can be severe. It may even be life-threatening in a few cases. Some people may have GvHD over many months or even years.
The Global Graft-Versus-Host Disease (GVHD) Market was valued at $ XX Mn in 2018 and is forecast to grow at a XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The market value can be attributed to the increasing awareness and concerns regarding the health of patients.
According to the Center for International Blood and Marrow Transplant Research, there are about 25,000 allogeneic stem cell transplants are performed per year globally, affects a half or more of recipients, almost more than half of these cases could have been avoided with the availability of proper medical equipment and devices for healthcare procedures. This significant number is expected to act as a driver to market growth.
The Global Graft-Versus-Host Disease (GVHD) Market is segmented on the basis of product type, treatment type, end-user, and region.
Based on the Product Type: Corticosteroids, ATG therapies, IL2Rα (CD25) inhibitors, Others
Based on the Treatment Type: Prophylaxis GVHD, Acute GVHD, Chronic GVHD
Based on the End User: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
Based on the Region: North America, Asia-Pacific, Europe, and LAMEA.
North America held the largest share of the market, Strong regulatory framework for promoting cellular therapy development, high cost of therapies in the U.S.,
The key players of the Global Graft-Versus-Host Disease (GVHD) Market include Sanofi, Novartis AG, Amgen, Soligenix, Bristol-Myers Squibb, Merck & Co., Inc., Astellas Pharma, Mesoblast Ltd., Johnson & Johnson, Mallinckrodft, ElsaLys Biotech SA, Incyte Corporation, Kiadis Pharma and others.
The report covers in-depth analysis of the Global Graft-Versus-Host Disease (GVHD) Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), By Product Type (Corticosteroids, ATG therapies, IL2Rα (CD25) inhibitors, Others), Treatment Type (Prophylaxis GVHD, Acute GVHD, Chronic GVHD), End-User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in the Global Graft-Versus-Host Disease (GVHD) Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary databases and Models)
Market-related information is assembled from both primary and secondary sources.
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.